Peer Insights on Once-Daily Weight Management Therapy at endo 2026

Effective weight management in adults with obesity or overweight and weight-related comorbidities necessitates a multifaceted approach, frequently involving dietary modification, increased physical activity, and pharmacotherapy. Adherence to prescribed regimens remains a critical determinant of treatment success. The introduction of once-daily treatment options aims to address adherence barriers by simplifying the therapeutic schedule, thereby potentially improving sustained engagement with treatment. This approach is particularly relevant for chronic conditions like obesity, where long-term consistency is paramount for achieving and maintaining clinically meaningful weight reduction.¹

Clinical Perspectives on Once-Daily Therapy

Discussions among endocrinology specialists at endo 2026 centred on the practical application and perceived benefits of a once-daily treatment for weight management. Clinicians noted that the convenience of a single daily dose could reduce the burden associated with complex medication schedules, which often contributes to non-adherence. This simplification is particularly advantageous for patients managing multiple chronic conditions, where polypharmacy is common. The perceived ease of integration into daily routines was frequently cited as a factor that could improve patient persistence with therapy over extended periods.²

Expert opinion highlighted the importance of patient selection for this once-daily regimen. Appropriate adult patients are typically those with a body mass index (BMI) of 30 kg/m² or greater (obesity), or a BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia. The treatment is intended as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone intervention.³

Regarding efficacy, clinicians reported observing clinically relevant weight loss in patients receiving the once-daily treatment, consistent with data from pivotal trials. While specific numerical data (e.g., mean percentage weight loss, proportion of patients achieving a 5% or 10% weight reduction) were not presented in this peer insight session, the general consensus affirmed the treatment's capacity to support weight reduction goals. The mechanism of action, typically involving appetite regulation and satiety enhancement, was acknowledged as contributing to these observed effects.⁴

Tolerability was another key area of discussion. Specialists reported that the once-daily treatment was generally well-tolerated in their patient cohorts. Common adverse events, when they occurred, were typically gastrointestinal in nature, such as nausea, diarrhoea, or constipation, and were often transient and mild-to-moderate in severity. These events were frequently managed by dose titration or symptomatic treatment, allowing most patients to continue therapy. The low incidence of severe adverse events was considered a positive attribute, supporting the long-term safety profile necessary for chronic weight management.⁵

Limitations of the peer insight format include the absence of new, specific trial data and the reliance on anecdotal clinical experience rather than rigorously controlled study outcomes. While valuable for understanding real-world application, these insights do not replace the need for robust, large-scale clinical trials to definitively establish comparative efficacy and long-term safety against existing and emerging therapies. Future research should focus on head-to-head comparisons and real-world evidence studies to further delineate the precise role of once-daily treatments within the broader weight management landscape. The economic implications and accessibility of such treatments also warrant further investigation to ensure equitable patient access.⁶